Rocket Pharmaceuticals Competitors

Rocket Pharmaceuticals (NASDAQ:RCKT) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Rocket Pharmaceuticals and Grifols, as reported by MarketBeat.

Rocket Pharmaceuticals currently has a consensus price target of $57.8889, indicating a potential upside of 6.83%. Given Rocket Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Rocket Pharmaceuticals is more favorable than Grifols.

Volatility and Risk

Rocket Pharmaceuticals has a beta of 2.05, suggesting that its stock price is 105% more volatile than the S&P 500. Comparatively, Grifols has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500.

Profitability

This table compares Rocket Pharmaceuticals and Grifols' net margins, return on equity and return on assets.

Insider and Institutional Ownership

15.2% of Grifols shares are held by institutional investors. 41.4% of Rocket Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Rocket Pharmaceuticals and Grifols' gross revenue, earnings per share (EPS) and valuation.

Grifols has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Summary

Grifols beats Rocket Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Rocket Pharmaceuticals (NASDAQ:RCKT) and Bausch Health Companies (NYSE:BHC) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Rocket Pharmaceuticals and Bausch Health Companies, as reported by MarketBeat.

Rocket Pharmaceuticals currently has a consensus price target of $57.8889, indicating a potential upside of 6.83%. Bausch Health Companies has a consensus price target of $30.5833, indicating a potential downside of 3.37%. Given Rocket Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Rocket Pharmaceuticals is more favorable than Bausch Health Companies.

Volatility and Risk

Rocket Pharmaceuticals has a beta of 2.05, suggesting that its stock price is 105% more volatile than the S&P 500. Comparatively, Bausch Health Companies has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500.

Profitability

This table compares Rocket Pharmaceuticals and Bausch Health Companies' net margins, return on equity and return on assets.

Insider and Institutional Ownership

62.9% of Bausch Health Companies shares are held by institutional investors. 41.4% of Rocket Pharmaceuticals shares are held by company insiders. Comparatively, 12.1% of Bausch Health Companies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Rocket Pharmaceuticals and Bausch Health Companies' gross revenue, earnings per share (EPS) and valuation.

Rocket Pharmaceuticals has higher earnings, but lower revenue than Bausch Health Companies. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.

Summary

Rocket Pharmaceuticals beats Bausch Health Companies on 7 of the 13 factors compared between the two stocks.

Rocket Pharmaceuticals (NASDAQ:RCKT) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Rocket Pharmaceuticals and Dr. Reddy's Laboratories, as reported by MarketBeat.

Rocket Pharmaceuticals currently has a consensus price target of $57.8889, indicating a potential upside of 6.83%. Dr. Reddy's Laboratories has a consensus price target of $70.00, indicating a potential upside of 16.01%. Given Dr. Reddy's Laboratories' stronger consensus rating and higher possible upside, analysts clearly believe Dr. Reddy's Laboratories is more favorable than Rocket Pharmaceuticals.

Volatility and Risk

Rocket Pharmaceuticals has a beta of 2.05, suggesting that its stock price is 105% more volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500.

Profitability

This table compares Rocket Pharmaceuticals and Dr. Reddy's Laboratories' net margins, return on equity and return on assets.

Insider and Institutional Ownership

12.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 41.4% of Rocket Pharmaceuticals shares are held by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Rocket Pharmaceuticals and Dr. Reddy's Laboratories' gross revenue, earnings per share (EPS) and valuation.

Dr. Reddy's Laboratories has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Summary

Dr. Reddy's Laboratories beats Rocket Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

Rocket Pharmaceuticals (NASDAQ:RCKT) and Mirati Therapeutics (NASDAQ:MRTX) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Rocket Pharmaceuticals and Mirati Therapeutics, as reported by MarketBeat.

Rocket Pharmaceuticals currently has a consensus price target of $57.8889, indicating a potential upside of 6.83%. Mirati Therapeutics has a consensus price target of $219.0714, indicating a potential upside of 9.55%. Given Mirati Therapeutics' higher possible upside, analysts clearly believe Mirati Therapeutics is more favorable than Rocket Pharmaceuticals.

Volatility and Risk

Rocket Pharmaceuticals has a beta of 2.05, suggesting that its stock price is 105% more volatile than the S&P 500. Comparatively, Mirati Therapeutics has a beta of 1.64, suggesting that its stock price is 64% more volatile than the S&P 500.

Profitability

This table compares Rocket Pharmaceuticals and Mirati Therapeutics' net margins, return on equity and return on assets.

Insider and Institutional Ownership

94.9% of Mirati Therapeutics shares are held by institutional investors. 41.4% of Rocket Pharmaceuticals shares are held by company insiders. Comparatively, 4.1% of Mirati Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Rocket Pharmaceuticals and Mirati Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Rocket Pharmaceuticals has higher earnings, but lower revenue than Mirati Therapeutics. Mirati Therapeutics is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Rocket Pharmaceuticals beats Mirati Therapeutics on 8 of the 12 factors compared between the two stocks.

Rocket Pharmaceuticals (NASDAQ:RCKT) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Rocket Pharmaceuticals and BridgeBio Pharma, as reported by MarketBeat.

Rocket Pharmaceuticals currently has a consensus price target of $57.8889, indicating a potential upside of 6.83%. BridgeBio Pharma has a consensus price target of $61.2222, indicating a potential downside of 11.39%. Given Rocket Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Rocket Pharmaceuticals is more favorable than BridgeBio Pharma.

Volatility and Risk

Rocket Pharmaceuticals has a beta of 2.05, suggesting that its stock price is 105% more volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.

Profitability

This table compares Rocket Pharmaceuticals and BridgeBio Pharma's net margins, return on equity and return on assets.

Insider and Institutional Ownership

95.5% of BridgeBio Pharma shares are held by institutional investors. 41.4% of Rocket Pharmaceuticals shares are held by company insiders. Comparatively, 40.3% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Rocket Pharmaceuticals and BridgeBio Pharma's gross revenue, earnings per share (EPS) and valuation.

Rocket Pharmaceuticals has higher earnings, but lower revenue than BridgeBio Pharma. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

Rocket Pharmaceuticals beats BridgeBio Pharma on 9 of the 12 factors compared between the two stocks.

Rocket Pharmaceuticals (NASDAQ:RCKT) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings.

Profitability

This table compares Rocket Pharmaceuticals and Jazz Pharmaceuticals' net margins, return on equity and return on assets.

Volatility and Risk

Rocket Pharmaceuticals has a beta of 2.05, suggesting that its stock price is 105% more volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500.

Valuation and Earnings

This table compares Rocket Pharmaceuticals and Jazz Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Jazz Pharmaceuticals has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

95.7% of Jazz Pharmaceuticals shares are held by institutional investors. 41.4% of Rocket Pharmaceuticals shares are held by company insiders. Comparatively, 4.6% of Jazz Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Rocket Pharmaceuticals and Jazz Pharmaceuticals, as reported by MarketBeat.

Rocket Pharmaceuticals currently has a consensus price target of $57.8889, indicating a potential upside of 6.83%. Jazz Pharmaceuticals has a consensus price target of $181.00, indicating a potential upside of 6.14%. Given Rocket Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Rocket Pharmaceuticals is more favorable than Jazz Pharmaceuticals.

Summary

Jazz Pharmaceuticals beats Rocket Pharmaceuticals on 9 of the 13 factors compared between the two stocks.